(Q44053738)

English

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

scientific article published in April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 November 2017

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. (English)

1 reference

Europe PubMed Central

29 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thomas L. Richie

7

1 reference

Europe PubMed Central

29 November 2017

Stephen L. Hoffman

22

object named as

Stephen L Hoffman

1 reference

Europe PubMed Central

29 November 2017

D. Gray Heppner

9

object named as

D Gray Heppner

1 reference

Europe PubMed Central

29 November 2017

author name string

Judith E Epstein

1

1 reference

Europe PubMed Central

29 November 2017

Yupin Charoenvit

2

1 reference

Europe PubMed Central

29 November 2017

Kent E Kester

3

1 reference

Europe PubMed Central

29 November 2017

Ruobing Wang

4

1 reference

Europe PubMed Central

29 November 2017

Rhonda Newcomer

5

1 reference

Europe PubMed Central

29 November 2017

Steve Fitzpatrick

6

1 reference

Europe PubMed Central

29 November 2017

Nadia Tornieporth

8

1 reference

Europe PubMed Central

29 November 2017

Chris Ockenhouse

10

1 reference

Europe PubMed Central

29 November 2017

Victoria Majam

11

1 reference

Europe PubMed Central

29 November 2017

Carolyn Holland

12

1 reference

Europe PubMed Central

29 November 2017

Esteban Abot

13

1 reference

Europe PubMed Central

29 November 2017

Harini Ganeshan

14

1 reference

Europe PubMed Central

29 November 2017

Mara Berzins

15

1 reference

Europe PubMed Central

29 November 2017

Trevor Jones

16

1 reference

Europe PubMed Central

29 November 2017

C Nicole Freydberg

17

1 reference

Europe PubMed Central

29 November 2017

Jennifer Ng

18

1 reference

Europe PubMed Central

29 November 2017

Jon Norman

19

1 reference

Europe PubMed Central

29 November 2017

Daniel J Carucci

20

1 reference

Europe PubMed Central

29 November 2017

Joe Cohen

21

1 reference

Europe PubMed Central

29 November 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

29 November 2017

1 reference

Europe PubMed Central

29 November 2017

22

1 reference

Europe PubMed Central

29 November 2017

1592-1603

1 reference

Europe PubMed Central

29 November 2017

13-14

1 reference

Europe PubMed Central

29 November 2017

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

The complexity of protective immunity against liver-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

An OspA-Based DNA Vaccine Protects Mice against Infection with Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.01.031

7 January 2021

Identifiers

10.1016/J.VACCINE.2004.01.031

1 reference

Europe PubMed Central

29 November 2017

1 reference

Europe PubMed Central

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44053738&oldid=2106065188"